May 2021 tender notification

31 May 2021

Medicines Tender Closed

PHARMAC is pleased to provide the latest tender results.

Tender results

PHARMAC has resolved to award tenders for Principal Supply Status for some products included in the 2020/21 Invitation to Tender, dated 2 November 2020.

Some of the pharmaceuticals that will be delisted when the period of Principal Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms, Containered Trade Product Pack (CTPP) codes and Pharmacodes

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to PHARMAC, the Pharmacy Guild and the NZULM by:

For new listings, by 4pm on 12 June 2021 or the 5^th of the month prior to listing, whichever is earlier
For price changes, by 4pm on the 12^th of the month prior to the date of subsidy change

PHARMAC cannot list a product (and pharmacies cannot claim) without this information.

More information about this process and NOPC forms can be found on our website.

Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand(external link) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines(external link).

Pharmacodes and CTPP codes must be provided to PHARMAC by the 5^th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest).

PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.

Tender results [PDF, 85 KB]

2020/21 Tender – Principal Supply Status applies until 30 June 2024

CORRECTION to February 2021 tender notification

PHARMAC incorrectly notified a Principal Supply Status award in the Community and Hospital in February 2021 for betamethasone dipropionate with calcipotriol as ‘tube’ when this should have been a ‘bottle’. Correction in strikethrough and bold below:

1. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	Date of subsidy change	Principal Supply date
Betamethasone dipropionate with calcipotriol	Gel 500 mcg with calcipotriol 50 mcg per g, 60 g tube bottle	$52.24	$39.35	Daivobet (LEO Pharma)	1 July 2021	1 December 2021

2. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV Limit	Listing date	Principal Supply Status date
Betamethasone dipropionate with calcipotriol	Gel 500 mcg with calcipotriol 50 mcg per g, 60 g tube bottle	$52.24	$39.35	Daivobet (LEO Pharma)	5%	1 July 2021	1 December 2021

2020/21 Tender – Principal Supply Status applies until 30 June 2024

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

3. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	Date of subsidy change	Principal Supply date
Modafinil¹	Tab 100 mg; 60 tablet blister pack	$64.00	$29.13	Modavigil (Teva)	1 October 2021	1 March 2022
¹This product will be supplied at the Price from the 1st day of the month prior to the listing date, as per Schedule 5, clause 3.1 (b)(ii) of the 2020/21 Invitation To Tender.

See table 5 below for changes to the Pharmaceutical Schedule in relation to azacitidine.

4. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	Date of subsidy change	Principal Supply date	Brand (Supplier affected by delisting)
Flucloxacillin cap	cap 250 mg; 250 capsule bottle	$16.83	$15.79	Flucloxacillin-AFT (AFT)	1 December 2021	1 May 2022	Staphlex (Mylan)
Flucloxacillin cap	cap 500 mg; 500 capsule bottle	$56.61	$52.99	Flucloxacillin-AFT (AFT)	1 December 2021	1 May 2022	Staphlex (Mylan)
Melatonin²	Tab modified-release 2 mg; 30 tablet blister pack	$28.22	$11.50	Vigisom (Aspen Pharma)	1 November 2021	1 April 2022	Circadin (Aspen Pharma)
Travoprost	Eye drops 0.004%; 2.5 ml OP	$19.50	$9.75	Travatan (pharmacode 2550091)(Novartis)	1 July 2021	1 December 2021	Travatan (pharmacode 2144581) (Novartis) Mylan (pharmacode 2602296) (Mylan) Travopt (pharmacode 2523035) (Mylan)
² Brand switch fee of $4.50 is payable for this product from 1 April 2022 to 30 June 2022

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

5. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV Limit	Listing date	Principal Supply Status date
Azacitidine³	Inj 100 mg vial, 1 vial pack	$139.00	$75.06	Azacitidine Dr Reddy’s (Dr Reddy’s)	5%	1 July 2021	1 December 2021
Linezolid	Inj 2 mg per ml; 300 ml bottle	$18.50 (per 1)	$155.00 (per 10)	Linezolid Kabi (Fresenius Kabi)	5%	1 July 2021	1 December 2021
Modafinil⁴	Tab 100 mg; 60 tablet blister pack	$64.00	$29.13	Modavigil (Teva)	5%	1 October 2021	1 March 2022
³ The price and subsidy of azacitidine (PCT only – Specialist) in Section B of the Pharmaceutical Schedule will also be amended to the above prices from 1 July 2021. The subsidy of azacitidine (Baxter) inj 1 mg for ECP in Section B of the Pharmaceutical Schedule will also be amended from $1.53 per 1 mg to $0.83 per 1 mg from 1 July 2021. ⁴This product will be supplied at the Price from the 1^st day of the month prior to the listing date, as per Schedule 6, clause 3.1 (b)(ii) of the 2020/21 Invitation To Tender.

6. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV Limit	Listing date	Principal Supply Status date	Brand (Supplier) affected by delisting
Flucloxacillin cap	cap 250 mg; 250 capsule bottle	$16.83	$15.79	Flucloxacillin-AFT (AFT)	5%	1 December 2021	1 May 2022	Staphlex (Mylan)
Flucloxacillin cap	cap 500 mg; 500 capsule bottle	$56.61	$52.99	Flucloxacillin-AFT (AFT)	5%	1 December 2021	1 May 2022	Staphlex (Mylan)
Melatonin	Tab modified-release 2 mg; 30 tablet blister pack	$28.22	$11.50	Vigisom (Aspen Pharma)	5%	1 November 2021	1 April 2022	Circadin (Aspen Pharma)
Milrinone	Inj 1 mg per ml, 10 ml ampoule; 10 ampoule pack	$99.00	$71.00	Milrinone-Baxter (Baxter)	5%	1 July 2021	1 December 2021	Primacor (Sanofi-Aventis)
Travoprost	Eye drops 0.004%; 2.5 ml	$19.50	$9.75	Travatan (pharmacode 2550091) (Novartis)	5%	1 July 2021	1 December 2021	Travopt (Mylan)

Tender declines - Products where no tender is to be awarded for Principal Supply Status, Sole Subsidised Supply Status or Hospital Supply Status

PHARMAC has resolved not to award tenders for Principal Supply Status, Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in:

the 2020/21 Invitation to Tender, dated 2 November 2020
the 2019/20 Invitation to Tender, dated 1 November 2019

2020/21 Invitation to Tender

Chemical name	Line item
Alprostadil	Inj 500 mcg per ml, 1 ml
Azacitidine (widened access)	Inj 100 mg
Azithromycin	Grans for oral liq 200 mg per 5 ml
Cabergoline	Tab 0.5 mg (2 pack)
Cabergoline	Tab 0.5 mg (8 pack)
Calcium Gluconate	Inj 10%, 10 ml
Cisplatin	Inj 1 mg per ml, 50 ml
Desferrioxamine mesilate	Inj 500 mg
Diclofenac sodium	Inj 25 mg per ml, 3 ml
Diclofenac sodium	Suppos 100 mg
Diclofenac sodium	Suppos 12.5 mg
Diclofenac sodium	Suppos 25 mg
Diclofenac sodium	Suppos 50 mg
Diclofenac sodium	Tab 50 mg dispersible
Disopyramide phosphate	Cap 100 mg
Efavirenz	Tab 200 mg
Efavirenz	Tab 50 mg
Efavirenz	Tab 600 mg
Efavirenz	Oral liq 30 mg per ml
Ferrous sulphate with ascorbic acid	tab long-acting 325 mg (105 mg elemental) with ascorbic acid 500
Glyceryl trinitrate	Inj 1 mg per mL, 10 mL
Hydrocortisone	Oint 1% (pack size greater than 100 g)
Hydrocortisone	Oint 1% (pack size 100 g or less)
Idarubicin Hydrochloride	Inj 10 mg
Idarubicin Hydrochloride	Inj 5 mg
Lidocaine [Lignocaine] Hydrochloride	Gel 2%
Lopinavir with Ritonavir	Oral liq 80 mg with ritonavir 20 mg per ml
Netupitant with Palonosetron	Cap netupitant 300 mg with palonosetron 500 mcg
Noradrenaline	Inj 0.06 mg per ml, 100 ml bag
Noradrenaline	Inj 0.12 mg per ml, 50 ml syringe
Noradrenaline	Inj 0.16 mg per ml, 100 ml bag
Noradrenaline	Inj 0.16 mg per ml, 50 ml vial
Noradrenaline	Inj 1 mg per ml, 100 ml bag
Pamidronate disodium	Inj 3 mg per ml, 10 ml
Pamidronate disodium	Inj 6 mg per ml, 10 ml
Pamidronate disodium	Inj 9 mg per ml, 10 ml
Pancreatic enzyme	Cap 175 mg
Povidone Iodine	Antiseptic soln 10% (pack size 15 ml or less)
Povidone Iodine	Antiseptic soln 10% (pack size greater than 100 ml)
Povidone Iodine	Skin preparation, povidone iodine 10% with 30% alcohol (pack size 100 ml or less)
Povidone Iodine	Skin preparation, povidone iodine 10% with 30% alcohol (pack size greater than 100 ml)
Povidone Iodine	Skin preparation, povidone iodine 10% with 70% alcohol (pack size 100 ml or less)
Povidone Iodine	Skin preparation, povidone iodine 10% with 70% alcohol (pack size greater than 100 ml)
Ziprasidone	Cap 80 mg

2019/20 Invitation to Tender

Insulin pen needles	29 g x 12.7 mm
Insulin pen needles	31 g x 5 mm
Insulin pen needles	31 g x 6 mm
Insulin pen needles	31 g x 8 mm
Insulin pen needles	32 g x 4 mm
Insulin syringes, disposable with attached needle:	0.3 ml with 29 g x 12.7 mm needle
Insulin syringes, disposable with attached needle:	0.3 ml with 31 g x 8 mm needle
Insulin syringes, disposable with attached needle:	0.3 ml with 29 g x 6 mm needle
Insulin syringes, disposable with attached needle:	0.5 ml with 29 g x 12.7 mm needle
Insulin syringes, disposable with attached needle:	0.5 ml with 31 g x 8 mm needle
Insulin syringes, disposable with attached needle:	0.5 ml with 29 g x 6 mm needle
Insulin syringes, disposable with attached needle:	1 ml with 29 g x 12.7 mm needle
Insulin syringes, disposable with attached needle:	1 ml with 31 g x 8 mm needle
Insulin syringes, disposable with attached needle:	1 ml with 29 g x 6 mm needle
Mupirocin	Intra-nasal ointment 2%
Mupirocin	Topical ointment 2%
Phenylephrine hydrochloride	Inj 10 mg per ml, 1 ml vial
Zinc	cream (pack size 50 g or less)
Zinc	cream (pack size greater than 50 g)
Zinc	ointment (pack size 50 g or less)
Zinc	ointment (pack size greater than 50 g)
Zinc	paste (pack size 50 g or less)

For products included in the 2018/19, 2019/20 and 2020/21 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made. If you have any queries regarding this notification, please contact PHARMAC on 0800 66 00 50.